The European Patent Office has granted patent number EP 2315580 B1 to Massachusetts biotech company Pulmatrix for “Pharmaceutical formulations and methods for treating respiratory tract infections.” The patent covers “both dry powder and liquid formulations with optimized ranges of the formulation components, and also describes methods for treating respiratory infections and diseases as well as methods for treating acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF),” according to the company.
Pulmatrix’s lead dry powder candidate, PUR118, is specifically covered by the patent. PUR118 is an iCALM (inhaled cationic airway lining modulator) formulation being developed as a treatment for COPD, asthma, CF, and influenza. Pulmatrix is also developing a liquid formulation and a number of iCALM combination formulations.
Pulmatrix CEO Robert Connelly said, “We are pleased that our proprietary technology has been recognized by the European Patent Office, both for its unique formulations as well as its methods of use in treating respiratory diseases and infections. With composition of matter claims from this grant and other granted patents, we are very confident that our full intellectual property portfolio will protect our iCALM and iSPERSE platforms for delivering both standalone and combination therapies that could offer significant unique benefits to patients.”
An additional 100 patent applications are pending worldwide, the company says, in addition to 7 granted patents.
Read the Pulmatrix press release.
